{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:18:20Z","timestamp":1791260300014,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"American Foundation of Pharmaceutical Education (AFPE) Gateway to Research Award","award":["AARGD-NTF-22-972749"],"award-info":[{"award-number":["AARGD-NTF-22-972749"]}]},{"name":"American Foundation of Pharmaceutical Education (AFPE) Gateway to Research Award","award":["1R03AG080418-01"],"award-info":[{"award-number":["1R03AG080418-01"]}]},{"name":"American Foundation of Pharmaceutical Education (AFPE) Gateway to Research Award","award":["5R25HL105446-12"],"award-info":[{"award-number":["5R25HL105446-12"]}]},{"name":"the University of Toledo Office of Research and Sponsored Programs","award":["AARGD-NTF-22-972749"],"award-info":[{"award-number":["AARGD-NTF-22-972749"]}]},{"name":"the University of Toledo Office of Research and Sponsored Programs","award":["1R03AG080418-01"],"award-info":[{"award-number":["1R03AG080418-01"]}]},{"name":"the University of Toledo Office of Research and Sponsored Programs","award":["5R25HL105446-12"],"award-info":[{"award-number":["5R25HL105446-12"]}]},{"name":"Alzheimer\u2019s Association","award":["AARGD-NTF-22-972749"],"award-info":[{"award-number":["AARGD-NTF-22-972749"]}]},{"name":"Alzheimer\u2019s Association","award":["1R03AG080418-01"],"award-info":[{"award-number":["1R03AG080418-01"]}]},{"name":"Alzheimer\u2019s Association","award":["5R25HL105446-12"],"award-info":[{"award-number":["5R25HL105446-12"]}]},{"name":"NIA","award":["AARGD-NTF-22-972749"],"award-info":[{"award-number":["AARGD-NTF-22-972749"]}]},{"name":"NIA","award":["1R03AG080418-01"],"award-info":[{"award-number":["1R03AG080418-01"]}]},{"name":"NIA","award":["5R25HL105446-12"],"award-info":[{"award-number":["5R25HL105446-12"]}]},{"name":"NHLBI","award":["AARGD-NTF-22-972749"],"award-info":[{"award-number":["AARGD-NTF-22-972749"]}]},{"name":"NHLBI","award":["1R03AG080418-01"],"award-info":[{"award-number":["1R03AG080418-01"]}]},{"name":"NHLBI","award":["5R25HL105446-12"],"award-info":[{"award-number":["5R25HL105446-12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Polycystic kidney disease (PKD), a ciliopathy caused primarily by mutations in the Pkd1 and Pkd2 genes, disrupts renal structure and function, leading to progressive renal failure. The primary cilium, a sensory organelle essential for cellular signaling, plays a pivotal role in maintaining renal function. Among its signaling components, G-protein-coupled receptors (GPCRs) within the cilium have gained significant attention for their localized functions and their contribution to PKD pathogenesis. Dysfunction of ciliary GPCR signaling alters key downstream pathways, including mammalian target of rapamycin (mTOR), cyclic adenosine monophosphate (cAMP), and calcium homeostasis, exacerbating cyst formation and disease progression. Additionally, interactions between ciliary GPCRs and PKD-associated proteins, such as Polycystin-1 (PC1) and Polycystin-2 (PC2), underline the complexity of PKD mechanisms. Recent advances highlight GPCRs as promising therapeutic targets for ciliopathies, including PKD. Emerging GPCR modulators and drugs in clinical trials show the potential to restore ciliary signaling and attenuate disease progression. This paper explores the physiological functions of ciliary GPCRs, their mechanistic links to PKD, and the therapeutic implications of targeting these receptors, offering insights into future research directions and therapeutic strategies for PKD.<\/jats:p>","DOI":"10.3390\/ijms26114971","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T04:32:37Z","timestamp":1747888357000},"page":"4971","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease"],"prefix":"10.3390","volume":"26","author":[{"given":"Raghad","family":"Buqaileh","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-5311","authenticated-orcid":false,"given":"Lubna A.","family":"Alshriem","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA"},{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8226-3108","authenticated-orcid":false,"given":"Wissam","family":"AbouAlaiwi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, University of Toledo, Toledo, OH 43614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"ref_1","first-page":"69","article-title":"Polycystic kidney disease: Inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Maser, R.L., Calvet, J.P., and Parnell, S.C. (2022). The GPCR properties of polycystin-1 A new paradigm. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1035507"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhuang, J., Aierken, A., Yalikun, D., Zhang, J., Wang, X., Ren, Y., Tian, X., and Jiang, H. (2023). Case report: Genotype-phenotype characteristics of nine novel PKD1 mutations in eight Chinese patients with autosomal dominant polycystic kidney disease. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1268307"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1113\/JP270933","article-title":"Structural studies of the C-terminal tail of polycystin-2 (PC2) reveal insights into the mechanisms used for the functional regulation of PC2","volume":"594","author":"Yang","year":"2016","journal-title":"J. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Brill, A.L., Fischer, T.T., Walters, J.M., Marlier, A., Sewanan, L.R., Wilson, P.C., Johnson, E.K., Moeckel, G., Cantley, L.G., and Campbell, S.G. (2020). Polycystin 2 is increased in disease to protect against stress-induced cell death. Sci. Rep., 10.","DOI":"10.1038\/s41598-019-57286-x"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1681\/ASN.2016040425","article-title":"Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context","volume":"27","author":"Leonhard","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/s41467-019-12067-y","article-title":"Ciliary exclusion of Polycystin-2 promotes kidney cystogenesis in an autosomal dominant polycystic kidney disease model","volume":"10","author":"Walker","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109649","DOI":"10.1016\/j.cellsig.2020.109649","article-title":"Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling","volume":"72","author":"Sussman","year":"2020","journal-title":"Cell Signal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102423","DOI":"10.3748\/wjg.v31.i12.102423","article-title":"To activate a G protein-coupled receptor permanently with cell surface photodynamic action in the gastrointestinal tract","volume":"31","author":"Cui","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/path.4843","article-title":"Motile and non-motile cilia in human pathology: From function to phenotypes","volume":"241","author":"Mitchison","year":"2017","journal-title":"J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajpath.2017.08.031","article-title":"Primary cilia in brain development and diseases","volume":"188","author":"Youn","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41580-019-0116-4","article-title":"Establishing and regulating the composition of cilia for signal transduction","volume":"20","author":"Nachury","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/BC20100139","article-title":"Ultrastructure of cilia and flagella\u2013back to the future!","volume":"103","author":"Fisch","year":"2011","journal-title":"Biol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/jcs.050377","article-title":"The primary cilium at a glance","volume":"123","author":"Satir","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrm952","article-title":"Intraflagellar transport","volume":"3","author":"Rosenbaum","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.tcb.2023.05.005","article-title":"Regulation of the length of neuronal primary cilia and its potential effects on signalling","volume":"33","author":"Macarelli","year":"2023","journal-title":"Trends Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrn2789","article-title":"Olfactory signalling in vertebrates and insects: Differences and commonalities","volume":"11","author":"Kaupp","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1476-5381.2011.01434.x","article-title":"GPCR expression in tissues and cells: Are the optimal receptors being used as drug targets?","volume":"165","author":"Insel","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature14663","article-title":"Universal allosteric mechanism for Galpha activation by GPCRs","volume":"524","author":"Flock","year":"2015","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, N., Wang, Y., Li, T., and Feng, X. (2021). G-Protein Coupled Receptors (GPCRs): Signaling Pathways, Characterization, and Functions in Insect Physiology and Toxicology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105260"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","article-title":"How Ligands Illuminate GPCR Molecular Pharmacology","volume":"170","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41594-017-0011-7","article-title":"Structure and dynamics of GPCR signaling complexes","volume":"25","author":"Hilger","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1038\/sj.bjp.0707656","article-title":"Kinetics of G-protein-coupled receptor signals in intact cells","volume":"153","author":"Lohse","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11626","DOI":"10.1074\/jbc.REV120.009348","article-title":"Structural insights into emergent signaling modes of G protein-coupled receptors","volume":"295","author":"Sutkeviciute","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hoare, S.R., Tewson, P.H., Quinn, A.M., Hughes, T.E., and Bridge, L.J. (2020). Analyzing kinetic signaling data for G-protein-coupled receptors. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-67844-3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2017.11.033","article-title":"Pharmacogenomics of GPCR Drug Targets","volume":"172","author":"Hauser","year":"2018","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature08144","article-title":"The structure and function of G-protein-coupled receptors","volume":"459","author":"Rosenbaum","year":"2009","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuroscience.2012.02.033","article-title":"beta adrenergic receptor modulation of neurotransmission to cardiac vagal neurons in the nucleus ambiguus","volume":"210","author":"Bateman","year":"2012","journal-title":"Neuroscience"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ni.2812","article-title":"New nomenclature for atypical chemokine receptors","volume":"15","author":"Bachelerie","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(00)00185-3","article-title":"Gut hormones as pharmaceuticals: From enteroglucagon to GLP-1 and GLP-2","volume":"93","author":"Holst","year":"2000","journal-title":"Regul. Pept."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mykytyn, K., and Askwith, C. (2017). G-Protein-Coupled Receptor Signaling in Cilia. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a028183"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1173601","DOI":"10.3389\/fendo.2023.1173601","article-title":"V2 vasopressin receptor mutations: Future personalized therapy based on individual molecular biology","volume":"14","author":"Erdelyi","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/HYPERTENSIONAHA.111.00241","article-title":"The intrarenal renin-angiotensin and dopaminergic systems: Control of renal sodium excretion and blood pressure","volume":"61","author":"Carey","year":"2013","journal-title":"Hypertension"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41440-024-01763-y","article-title":"G protein-coupled receptor kinases in hypertension: Physiology, pathogenesis, and therapeutic targets","volume":"47","author":"Zhang","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12964-024-01802-8","article-title":"Role of G protein coupled receptors in acute kidney injury","volume":"22","author":"Lv","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"12195","DOI":"10.1073\/pnas.0900130106","article-title":"Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists","volume":"106","author":"Robben","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drudis.2010.11.016","article-title":"Angiotensin II receptors and drug discovery in cardiovascular disease","volume":"16","author":"Dasgupta","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11906-012-0253-z","article-title":"Dopamine, the kidney, and hypertension","volume":"14","author":"Harris","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.15252\/embr.201540530","article-title":"Ins and outs of GPCR signaling in primary cilia","volume":"16","author":"Schou","year":"2015","journal-title":"EMBO Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Saternos, H.C., Forero, K.V., Meqdad, M.A., Buqaileh, R., Sunderman, C.L., Gallagher, G., Messer, W.S., Mohieldin, A.M., Mucci, C.A., and Kumariya, S. (2025). Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-87212-3"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"F706","DOI":"10.1152\/ajprenal.00172.2017","article-title":"Biophysics and biofluid dynamics of primary cilia: Evidence for and against the flow-sensing function","volume":"313","author":"Nag","year":"2017","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00424-008-0498-1","article-title":"Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption","volume":"456","author":"Boone","year":"2008","journal-title":"Pfl\u00fcgers Arch.-Eur. J. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","article-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors","volume":"306","author":"Juul","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: Physiology, assessment and osmosensation","volume":"282","author":"Bankir","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(01)00328-5","article-title":"Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects","volume":"51","author":"Bankir","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/jcp.30659","article-title":"Prostaglandin signaling in ciliogenesis and development","volume":"237","author":"Jin","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/HYPERTENSIONAHA.111.172080","article-title":"Dopamine receptor type 5 in the primary cilia has dual chemo-and mechano-sensory roles","volume":"58","author":"Nauli","year":"2011","journal-title":"Hypertension"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Upadhyay, V.S., Muntean, B.S., Kathem, S.H., Hwang, J.J., AbouAlaiwi, W.A., and Nauli, S.M. (2014). Roles of dopamine receptor on chemosensory and mechanosensory primary cilia in renal epithelial cells. Front. Physiol., 5.","DOI":"10.3389\/fphys.2014.00072"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Paul, P., Ramachandran, S., Xia, S., Unruh, J.R., Conkright-Fincham, J., and Li, R. (2019). Dopamine receptor antagonists as potential therapeutic agents for ADPKD. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216220"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","author":"Messchendorp","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","article-title":"Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney","volume":"280","author":"Balster","year":"2001","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1\u20135 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J. Histochem. Cytochem."},{"key":"ref_57","first-page":"8","article-title":"Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats","volume":"7","author":"Winkler","year":"1982","journal-title":"Miner. Electrolyte Metab."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bergmann, C. (2018). Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00221"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/emboj.2012.26","article-title":"A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis","volume":"31","author":"Boucard","year":"2012","journal-title":"EMBO J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000095133","article-title":"A regulatory role of polycystin-1 on cystic fibrosis transmembrane conductance regulator plasma membrane expression","volume":"18","author":"Ikeda","year":"2006","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41581-019-0116-9","article-title":"Cellular signalling by primary cilia in development, organ function and disease","volume":"15","author":"Anvarian","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Vasileva, V.Y., Sultanova, R.F., Sudarikova, A.V., and Ilatovskaya, D.V. (2021). Insights into the molecular mechanisms of polycystic kidney diseases. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.693130"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ma, M., Gallagher, A.-R., and Somlo, S. (2017). Ciliary mechanisms of cyst formation in polycystic kidney disease. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a028209"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/ncb2117","article-title":"Primary cilia regulate mTORC1 activity and cell size through Lkb1","volume":"12","author":"Boehlke","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"jcs260565","DOI":"10.1242\/jcs.260565","article-title":"Ciliary mechanosensation\u2014Roles of polycystins and mastigonemes","volume":"136","author":"Liu","year":"2023","journal-title":"J. Cell Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ctdb.2023.09.004","article-title":"Crosstalk between the mTOR pathway and primary cilia in human diseases","volume":"155","author":"Prosseda","year":"2023","journal-title":"Curr. Top. Dev. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lin, H.H., Ng, K.F., Chen, T.C., and Tseng, W.Y. (2022). Ligands and Beyond: Mechanosensitive Adhesion GPCRs. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020219"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Di Mise, A., Tamma, G., Ranieri, M., Centrone, M., van den Heuvel, L., Mekahli, D., Levtchenko, E.N., and Valenti, G. (2018). Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-23732-5"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1097-4679(197610)32:4<885::AID-JCLP2270320434>3.0.CO;2-R","article-title":"Aggressive behavior and the Rosenzweig Picture-Frustration (P-F) Study","volume":"32","author":"Rosenzweig","year":"1976","journal-title":"J. Clin. Psychol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrneph.2012.139","article-title":"An early urea-selective urine-concentrating defect in ADPKD","volume":"8","author":"Bankir","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: Optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.2009.267","article-title":"V1\/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin\u2013angiotensin system inhibition in rats with renal mass reduction","volume":"76","author":"Perico","year":"2009","journal-title":"Kidney Int."},{"key":"ref_83","first-page":"599","article-title":"Antagonism of vasopressin-induced water flow by somatostatin","volume":"24","author":"Strandhoy","year":"1979","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","article-title":"Somatostatin and \u03b12-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells","volume":"198","author":"Friedlander","year":"1986","journal-title":"FEBS Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"C1205","DOI":"10.1152\/ajpcell.00313.2002","article-title":"Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes","volume":"284","author":"Gong","year":"2003","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0928-4257(00)00206-0","article-title":"Signal transduction of somatostatin receptors negatively controlling cell proliferation","volume":"94","author":"Ferjoux","year":"2000","journal-title":"J. Physiol.-Paris"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032, 5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Perico, N., Ruggenenti, P., Perna, A., Caroli, A., Trillini, M., Sironi, S., Pisani, A., Riccio, E., Imbriaco, M., and Dugo, M. (2019). Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002777"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: A systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"key":"ref_93","first-page":"63","article-title":"Ciliotherapy: A novel intervention in polycystic kidney disease","volume":"11","author":"Kathem","year":"2014","journal-title":"J. Geriatr. Cardiol. JGC"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/4971\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:09Z","timestamp":1760031489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/4971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":93,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26114971"],"URL":"https:\/\/doi.org\/10.3390\/ijms26114971","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}